Rushad Patell
Hematology · Boston, MANPI 1740694702
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,009 of the $51,714 with a category attached, or 92.8%. Merck accounts for 67.0% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $50,139, more than ten times the $323 reported in 2020.
Across 38 payments — averaging $1360.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$35K
- Sanofi$15K
- Novartis$1K
- Octapharma USA, Inc.$868
- Novo Nordisk$323
Across 8 payments — averaging $20,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$148K
- Incyte Corporation$12K
What the payments were for
- Consulting fees$48,00993%
- Grants$3231%
- Travel & lodging$2,2494%
- Food & beverage$1,1332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $34,633 |
| Sanofi | 7 | $14,756 |
| Novartis | 5 | $1,134 |
| Octapharma USA, Inc. | 9 | $868 |
| Novo Nordisk | 1 | $323 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,714 in reported general payments places this provider in the 80th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DopteletAvatrombopag Maleate | 16 | $206,596 |
| EliquisApixaban | 33 | $24,019 |
| Hydroxyurea | 86 | $2,090 |
Paid to pharmacies, not to this prescriber.
Other hematology in Boston
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.